Riskpilot← Back to searchSign inGet full accessPharmanovia A/S
A/SActiveCVR 32287824Ørestads Boulevard 108, 5.Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20094 employees
Revenue 2025
DKK 6M
+29% vs 2024
EBITDA margin
63.9%
+25% vs 2024
Equity ratio
20.3%
Financial strength
Net profit 2025
DKK 3,8M
+71% vs 2024
| Revenue | DKK 6M | +29% |
| EBITDA | DKK 3,9M | +25% |
| Net profit | DKK 3,8M | +71% |
| Total assets | DKK 39,9M | -16% |
| Equity | DKK 8,1M | +66% |
| Employees | 4 | — |
Legal name
Pharmanovia A/S
CVR number
32287824
Legal form
Aktieselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
6. juli 2009
Share capital
DKK 1.000.001
Employees
4 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-03-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsens medlemmer hver for sig eller af en direktør alene.
Company purpose
Selskabets formål er at drive handelsvirksomhed med farmaceutiske produkter, herunder udvikling, salg, distribution og markedsføring af farmaceutiske produkter og dermed beslægtet virksomhed.
Address
Ørestads Boulevard 108, 5.
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -157 | -1.180 | -609 | 1.475 | 1.212 | 2.646 | 10.614 | 3.730 | 15.224 | 3.431 | 43.984 | 4.684 | 6.025 |
| Staff expenses | -416 | -3.239 | -1.669 | -2.129 | -5.526 | -6.256 | -10.637 | -13.352 | -15.840 | -15.917 | -18.458 | -1.607 | -2.172 |
| EBITDA | -572 | -4.419 | -2.277 | -654 | -4.314 | -3.610 | -27 | -9.622 | -617 | -12.485 | 25.526 | 3.077 | 3.852 |
| Depreciation & amort. | -108 | -529 | -546 | -787 | -2.604 | -4.272 | -802 | -2.131 | -1.183 | -7.651 | -601 | -152 | -148 |
| EBIT | -680 | -4.948 | -2.823 | -1.441 | -6.919 | -7.882 | -828 | -11.753 | -1.799 | -20.136 | 24.924 | 2.925 | 3.704 |
| Net financials | -100 | -1.614 | -581 | -748 | -919 | -1.355 | -5.063 | -1.962 | -229 | -1.464 | -469 | -243 | 128 |
| Profit before tax | -390 | -6.562 | -3.404 | -2.189 | -7.838 | -9.238 | -5.891 | -13.715 | -2.028 | -21.600 | 24.455 | 2.683 | 3.832 |
| Tax | 195 | 132 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -1.676 | 436 | -7 |
| Net profit | -586 | -6.694 | -3.404 | -2.189 | -7.838 | -9.238 | -5.891 | -13.715 | -2.028 | -21.600 | 26.131 | 2.247 | 3.839 |
| Item | 2012 | 2013 | 2014 | 2015 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 11.730 | 14.782 | 13.108 | 18.656 | 23.474 | 23.903 | 24.728 | 29.159 | 27.912 | 76.094 | 136.728 | 47.728 | 39.941 |
| Equity | -60 | -6.754 | -10.158 | -12.347 | -4.802 | -14.039 | -19.930 | 17.138 | 15.110 | -6.491 | 19.640 | 4.883 | 8.090 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 28.686 | 34.960 | 2.347 | 3.251 | 60.708 | 38.340 | 0 | 0 |
| Short-term debt | 11.790 | 21.535 | 23.266 | 31.003 | 28.277 | 9.256 | 9.699 | 9.674 | 9.551 | 21.877 | 78.748 | 42.844 | 31.576 |
| Total debt | 11.790 | 21.535 | 23.266 | 31.003 | 28.277 | 37.943 | 44.659 | 12.022 | 12.803 | 82.585 | 117.088 | 42.844 | 31.576 |
EBITDA margin
63.9%
This company
15.8%
Market median
+304% vs market
20122025
Equity ratio
20.3%
This company
38.2%
Market median
-47% vs market
20122025
Return on equity
47.5%
This company
18.4%
Market median
+158% vs market
20122025
Net profit margin
63.7%
This company
8.1%
Market median
+686% vs market
20122025
Asset turnover
0.15×
This company
1.12×
Market median
-87% vs market
20122025
Debt / equity
3.94×
This company
0.62×
Market median
-535% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2024-04-01 – 2025-03-31
- Annual report 2024Filed via CVR / Virk · Period 2023-04-01 – 2024-03-31
- Annual report 2023Filed via CVR / Virk · Period 2022-04-01 – 2023-03-31
- Annual report 2022Filed via CVR / Virk · Period 2021-04-01 – 2022-03-31
- Annual report 2021Filed via CVR / Virk · Period 2020-04-01 – 2021-03-31
- Annual report 2020Filed via CVR / Virk · Period 2019-04-01 – 2020-03-31
- Annual report 2019Filed via CVR / Virk · Period 2018-04-01 – 2019-03-31
- Annual report 2018Filed via CVR / Virk · Period 2017-04-01 – 2018-03-31
- Annual report 2017Filed via CVR / Virk · Period 2016-01-01 – 2017-03-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
NB Management | Management | 2025 | — | — |
JS Management | Management | 2023 | — | — |
JW Management | Management | 2019 | — | — |
MR Chief Executive Officer | Chief Executive Officer | 2013 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2016 | — | — | |
| Board of Directors | 2011 | — | — | |
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2013 | — | — | |
| Chairman | 2026 | — | — | |
| Chairman | 2016 | — | — | |
| Board of Directors | 2026 | — | — | |
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2025 | — | — | |
| Chairman | 2016 | — | — | |
| Deputy Chairman | 2016 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2026 | — | — | |
| Board of Directors | 2025 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2018 | |
| Individual | 33.3% | 33.3% | 2018 | |
Java Holding ApS | Company | 33.3% | 33.3% | 2016 |
CHRISJOPALI ApS | Company | 33.3% | 33.3% | 2016 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Pharmanovia A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Neeshe Bhikhubhai Williams | Management | 0 companies |
| James Sang Bum Lee | Management | 0 companies |
| Jesper Wilhelm Voss | Management | 0 companies |
| Mads Renlef Henningsen | Chief Executive Officer | 0 companies |
| Alastair Thomas Badgett Hay | Board of Directors | 0 companies |
| Anthony Charles Playle | Board of Directors | 0 companies |
| Mads Christian Olesen | Board of Directors | 0 companies |
| Rishi Bhikhu | Board of Directors | 0 companies |
| Birgitte Stenbjerre | Board of Directors | 0 companies |
| Mohammad Muqtadir Samy | Chairman | 0 companies |
| Bent Benny Andersen | Chairman | 0 companies |
| Twan Johannes Anna Nouwen | Board of Directors | 0 companies |
| Mark John Cotterill | Board of Directors | 0 companies |
| Zubair Javeed | Board of Directors | 0 companies |
| Amit Vijaykumar Patel | Chairman | 0 companies |
| Dipen Vijaykumar Patel | Deputy Chairman | 0 companies |
| Felipe Andres Florez Arango | Board of Directors | 0 companies |
| James Charles Burt | Board of Directors | 0 companies |
| Christoph Michael Habereder | Board of Directors | 0 companies |
| Santsagar Patel | Board of Directors | 0 companies |